Skip to main content

BB Biotech AG's Form 4 filing

Black Diamond Therapeutics, Inc. (BDTX) · filed Mar 20, 2025

Accession no.
0001104659-25-026305
Filed
Mar 20, 2025, 9:01 PM ET
Trade date
Mar 19, 2025
Filing delay
1 day
Rule 10b5-1 plan
Not checked

This filing lists 7 non-derivative transactions. Open-market sales total $12.0M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
BB Biotech AGCIK 000092422310% Owner
Biotech Growth N VCIK 000125986910% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 19, 2025Common StockSSaleDisposed−1,000,000$2.07−$2,069,1007,517,839Direct
Mar 19, 2025Common StockSSaleDisposed−300,000$1.94−$582,9007,217,839Direct
Mar 19, 2025Common StockSSaleDisposed−1,000,000$2.31−$2,308,1006,217,839Direct
Mar 19, 2025Common StockSSaleDisposed−2,000,000$2.00−$4,000,8004,217,839Direct
Mar 19, 2025Common StockSSaleDisposed−400,000$2.09−$837,1603,817,839Direct
Mar 19, 2025Common StockSSaleDisposed−584,292$1.95−$1,141,239.133,233,547Direct
Mar 19, 2025Common StockSSaleDisposed−500,000$2.12−$1,058,4502,733,547Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)